Observations placeholder
Certolizumab pegol and Cimzia
Identifier
017733
Type of Spiritual Experience
Number of hallucinations: 12
Background
A description of the experience
Certolizumab pegol (CDP870, tradename Cimzia) is a therapeutic monoclonal antibody to tumor necrosis factor alpha (TNF-α), for the treatment of Crohn's disease and rheumatoid arthritis.
On Jan, 18, 2017 23,550 people reported to have side effects when taking Cimzia. Among them, 12 people (0.05%) have Hallucination
Time on Cimzia when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 0.00% | 50.00% | 0.00% | 0.00% | 50.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Cimzia :
| Female | Male | |
| Hallucination | 25.00% | 75.00% |
Age of people who have Hallucination when taking Cimzia :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 75.00% |